Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (10896)	7/23/1999 3:41:00 PM
From: aknahow	Respond to of 17367

Not a matter of eye care. Specific license granted to AGN is for the use of BPI along with other antibiotics for anti infective purposes only. All the anti-angiogenensis properties have been retained by XOMA. They can do whatever they are able to with the retained properties of BPI including a license to someone else. Since we do not know what the terms of the negotiation were for the entire I-Prex package, we can't tell why AGN did not want the whole package nor what the remaining properties might be worth. One thing we do learn is that those who think "splice and dice" can't be done are wrong. Not only can the protein be split into various traunches, it appears that even the final products can be split into very specific applications. There is no way AGN can try to use BPI for some other purpose. And the fact that the BPI products of AGN will contain another antibiotic will make even off label use for other purposes unlikely.